Abstract
Hypertension is associated with alterations in the vascular structure, which in turn enhance the risk of cardiovascular events. Notably, anti-hypertensive treatment may prevent or regress the changes of arterial wall structures. Lercanidipine is a third-generation CCB with peculiar pharmaceutical properties. Enalapril is an effective drug acting on the renin–angiotensin–aldosterone axis. This commentary discusses the vascular effects of the lercanidipine/enalapril combination, and comments on their potential clinical relevance.
Transparency
Declaration of funding
Editorial assistance was supported by Recordati.
Declaration of financial/other relationships
G.P. has disclosed that he has no significant relationships with or financial interests in any commercial companies related to this study or article.
CMRO peer reviewers on this manuscript have received an honorarium for their review work but have no relevant financial or other relationships to disclose.
Acknowledgments
Editorial assistance for the preparation of this manuscript was provided by Luca Giacomelli PhD and Sara Parodi PhD of Content Ed Net.